InnoPharmax Inc. (TPEX:4172)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
14.65
-0.20 (-1.35%)
Apr 29, 2026, 1:53 PM CST
-6.69%
Market Cap 1.58B
Revenue (ttm) 68.99M
Net Income (ttm) -184.40M
Shares Out 107.58M
EPS (ttm) -1.71
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 175,828
Average Volume 724,642
Open 14.90
Previous Close 14.85
Day's Range 14.25 - 14.90
52-Week Range 12.75 - 23.75
Beta 0.05
RSI 49.03
Earnings Date Aug 10, 2026

About InnoPharmax

InnoPharmax Inc., a specialty pharmaceutical company, develops and commercializes products for the treatment of oncology and other specialties in Taiwan. The company offers Imipenem and Cilastatin sodium solution under the Bestnem brand for the treatment of infections caused by susceptible organisms, such as lower respiratory tract, skin and skin structure, intra-abdominal, gynecologic, bone, and joint infections; contrast agents, such as gadopentetate dimeglumine under the Gadomni brand; oncology agents comprising bendamustine under the Innomu... [Read more]

Sector Healthcare
Founded 1994
Employees 33
Stock Exchange Taipei Exchange
Ticker Symbol 4172
Full Company Profile

Financial Performance

In 2025, InnoPharmax's revenue was 68.99 million, an increase of 113.60% compared to the previous year's 32.30 million. Losses were -184.40 million, 85.7% more than in 2024.

Financial Statements

News

There is no news available yet.